Akeso and Summit Therapeutics announced that their PD‑1×VEGF bispecific antibody, ivonescimab, achieved a statistically significant improvement in overall survival (OS) compared with Merck’s Keytruda in a head‑to‑head clinical study. The trial involved Chinese patients with first‑line PD‑L1‑positive non‑small cell lung cancer (NSCLC) as part of the Harmoni‑2 study. While the OS benefit was confirmed, market response was subdued, contrasting with a stronger reaction to a progression‑free survival (PFS) advantage reported two years earlier. The fourth Phase 3 OS endpoint was met, and the Hong Kong market saw a brief 3.4% rise.
調査・レポート2026年9月18日•3分で読めます
Ivonescimab Shows Overall Survival Benefit Over Keytruda in Head-to-Head NSCLC Trial
Akeso and Summit Therapeutics reported that their PD‑1×VEGF bispecific antibody ivonescimab improved overall survival versus Merck’s Keytruda in a direct comparison trial for first‑line PD‑L1‑positive NSCLC, though market reaction was muted.
Pharmacountryチームがまとめました · 出典： KPA News
トピック：
評価
(0)
(0)
(0)
(0)
(0)
評価を残す